Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) shares were down 3.9% on Monday . The stock traded as low as $18.68 and last traded at $18.88. Approximately 3,197 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 287,131 shares. The stock had previously closed at $19.64.

Crinetics Pharmaceuticals Price Performance

The firm has a 50-day moving average price of $20.33 and a two-hundred day moving average price of $20.11.

Insider Activity

In other news, Director Matthew K. Fust sold 5,700 shares of the stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $20.96, for a total value of $119,472.00. Following the completion of the sale, the director now directly owns 12,536 shares of the company's stock, valued at $262,754.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Stephen F. Betz sold 4,168 shares of the company's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total value of $87,569.68. Following the completion of the transaction, the insider now directly owns 100,598 shares in the company, valued at $2,113,563.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 5,700 shares of the company's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total value of $119,472.00. Following the completion of the transaction, the director now owns 12,536 shares of the company's stock, valued at $262,754.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,062 shares of company stock valued at $252,770. 5.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Crinetics Pharmaceuticals Company Profile

(Get Rating)

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

Featured Stories

• Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
• Don't Give Up on These Q3 Losers
• The Anatomy of a Great Pension Plan
• 3 Safe Earnings Plays for a Risk-Off Market
• Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
• Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.